期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

慢性肾脏病-矿物质和骨代谢异常的研究进展 被引量：2

Research progress in chronic kidney disease-mineral and bone disorder
暂未订购
导出
摘要 慢性肾脏病-矿物质和骨代谢异常(CKD-MBD)不仅提高心血管疾病的发生率,也是致死、骨折、生活质量下降及骨外组织钙化的重要原因。本文综述了CKD-MBD的发生机制、临床诊断、治疗措施三个方面的最新研究进展。 Chronic kidney disease-mineral and bone disorder （CKD-MBD） not only increases the incidence Of cardiovascular disease, but also causes death, fracture, decreased quality of life, and the extraskeletal calcification. In the present review we summarize the current progression on the mechanism, clinical diagnosis, and the treatment of CKD-MBD.
作者 张岩 顾洒洒 吴淑燕
机构地区 上海理工大学系统生物医学研究中心
出处 《中国骨质疏松杂志》 CAS CSCD 2011年第7期640-642,623,共4页 Chinese Journal of Osteoporosis
基金 上海市科学技术委员会资助(10PJ1407700) 上海市教育委员会科研创新项目(11ZZ137) 上海高校选拔培养优秀青年教师科研专项基金(slg10018)
关键词 肾脏病 骨代谢 甲状旁腺激素 高血磷 维生素D Kidney disease Bone metabolism Parathyroid hormone Hyperphosphatemia Vitamin D
分类号 R692 [医药卫生—泌尿科学]
  • 相关文献

参考文献25

  • 1Eddington H, Kalra PA. The association of chronic kidney disease-mineral bone disorder and cardiovascular risk. J Ren Care, 2010, 36 ( Suppl 1 ) :61-67.
  • 2Matuszkiewicz-Rowi~ska J. KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment ofmineral and bone disorders in chronic kidney disease. Pol Arch Med Wewn, 2010, 120(7-8) :300-306.
  • 3Moe SM, Drueke T. Improving global outcomes in mineral and bone disorders. Clin J Am Soe Nephrol,2008,3 ( Suppl 3 ) : 127- 130.
  • 4Souqiyyeh MZ, Shaheen FA. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidneydisease-mineral and bone disorder (CKD-MBD). Saudi Kidney Dis Tranapl, 2010, 21(1) :93-101.
  • 5Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patientswith chronic kidney disease : results of the study to evaluate early kidney disease. Kidney Int, 2007, 71 ( 1 ) :31-38.
  • 6Almaden Y, Felsenfeld A J, Rodfiguez M, et al. Proliferation in hyperplastie human and normal rat parathyroid glands: role ofphosphate, calcitriol, and gender. Kidney Int, 2003, 64 (6): 2311-2317.
  • 7Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soe Nephrol, 2005, 16(2) :520-528.
  • 8Toussaint ND, Elder GJ, Kerr PG. Bisphosphonates in chronic kidney disease ; balancing potential benefits and adverse effects on hone and soft tissue. Clin J Am Soc Nephrol, 2009, 4 ( 1 ) : 221-233.
  • 9陈靖.慢性肾脏病-矿物质和骨代谢异常发病机制的研究进展[J].临床肾脏病杂志,2010(4):148-150. 被引量：2
  • 10Souberbielle JC, Cavalier E, Jean G. Interpretation of serum parathyroid hormone concentrations in dialysis patients: what do the KDIGO guidelines change for the clinical laboratory? Clin Chem Lab Med, 2010, 48(6) :769-774.

二级参考文献13

  • 1Kevin D, Healy JV. Parathyroid hormone decreases renal vitamin D receptor expression in vivo [ J]. Proc Natl Acad Sci USA, 2005, 102(13) : 4724.
  • 2Benet - Pages A, Lorenz - Depiereux B, Zischka H, et al. FGF23 is processed by proprotein convertases but not by PHEX [ J]. Bone, 2004, 35: 455.
  • 3Orlando G, Tamara I, Eugene R, et al. Fibroblast growth factor- 23 mitigates hyperphosphatemia hut accentuates calcitriol deficiency in chronic kidney disease[ J]. Journal of the American Society of Nephrology,2005,16:2205.
  • 4Martinez I, Saracho R, Montenegro J, et al. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism [ J ]. Nephrol Dial Transplant, 1996,11 ( Suppl 3) : 22.
  • 5Block GA, Klassen PS, Lazarus JM,et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis[ J]. J Am Soc Ncpbrol,2004,15 : 2208.
  • 6Naional Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease[J]. Am J Kidney Dis, 2003,42: S1.
  • 7Llach F, Massry SG. On tile mechanism of secondary hyperparathyroidism in moderate renal insufficiency[ J]. J Clin Endocrinol Mctab, 1985,61 : 601.
  • 8Kazanla J, Sato F, Omori K, et al. Pretreatment serum FGF -23 levels predict the efficacy of calcitriol therapy in dialysis patients[J]. Kidney Int, 2005,67: 21120.
  • 9Arcidiacono MV, Sato T, Alvarez - Hernandez D, et al. EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease [ J ]. J Am Soc Nephrol, 2008,19 (2) : 310.
  • 10Steven Cheng, Daniel Coyne. Oral paricalcitol for the treatment of secondary hyperparathyroidism in chronic kidney disease[J]. J Am Soc Nephrol 2006, 2(3) : 297.

共引文献7

同被引文献15

  • 1Eddington H, Kalra PA. The association of chronic kidney disease-mineral bone disorder and cardiovascular risk [ J]. J Ren Care,2010,36( Suppl I) :61-67.
  • 2Kidney Disease:Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guide- line for the diagnosis, evaluation, prevention, and treat- ment of chronic kidney disease-mineral and bone disorder (CKD-MBD) [ J]. Kidney Int, 2009,76 ( Suppl 113 ) : 1-130.
  • 3Drechsler C, Grootendorst DC, Boeschoten EW, et al. Changes in parathyroid hormone, body mass index and the association with mortality in dialysis patients[ J]. Nephrol Dial Transplant ,2011,26 (4) : 1340-1346.
  • 4Snijder MB, van Dam RM, Visser M, et al. Adiposity in relation to vitamin D stat-us and parathyroid hormone lev-els: a population-based study in older men and women [ J ]. J Clin Endocrinol Metab, 2005,90 (7) :4119-4123.
  • 5de Mutsert R, Grootendorst DC, Boeschoten EW, et al. Subjective global assessent of nutritional status is strongly associated with mortality in chronic dialysis patients [ J ]. Am J Clin Nutr,2009,89(3):787-793.
  • 6Souberbielle JC, Cavalier E, Jean G. Interpretation of ser- um parathyroid hormone concentrations in dialysis pa- tients:what do the KDIGO guidelines change for the clin- ical laboratory [ J ]. Clin Chem Lab Med, 2010,48 ( 6 ) : 769-774.
  • 7Okuno S. Kidney and bone update:the 5-year history and future of CKD-MBD. Bone metabolic marker in hemodial- ysis patients update [ J ]. Clin Calcium, 2012,22 ( 7 ) : 1009-1017.
  • 8张凌.慢性肾脏病钙磷代谢紊乱及骨病的处理[J].中国实用内科杂志,2010,30(2):113-115. 被引量：40
  • 9孙桂芳,张宝霞.慢性肾脏病矿物质和骨代谢异常治疗进展[J].中外医疗,2010,29(29):183-184. 被引量：5
  • 10韩冰冰,周竹,翁敏.PAI-1在慢性肾脏病肾小球的表达及意义[J].当代医学,2011,17(11):1-4. 被引量：2

引证文献2

二级引证文献15

中国骨质疏松杂志
2011年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部